Skip to Content
Merck
CN
  • Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation (2008-11-26)
Sankar D Navaneethan, Sonal Singh, Suresh Appasamy, Richard E Wing, Ashwini R Sehgal
ABSTRACT

Optimal hydration measures to prevent contrast-induced nephropathy are controversial. We conducted a systematic review and meta-analysis using the MEDLINE database (1966 to January 2008), EMBASE (January 2008), and abstracts from conference proceedings. Adult patients undergoing contrast procedures. Randomized controlled trials comparing intravenous hydration with sodium bicarbonate with hydration with intravenous normal saline for prevention of contrast-induced nephropathy. Hydration with intravenous sodium bicarbonate with or without N-acetylcysteine versus hydration with normal saline with or without N-acetylcysteine. Contrast-induced nephropathy, need for renal replacement therapy, and worsening of heart failure. Twelve trials (1,854 participants) were included. Sodium bicarbonate significantly decreased the risk of contrast-induced nephropathy (12 trials, 1,652 patients; odds ratio [OR], 0.46; 95% confidence interval [CI], 0.26 to 0.82; I2 = 55.9%) without a significant difference in need for renal replacement therapy (9 trials, 1,215 patients; OR, 0.50; 95% CI, 0.16 to 1.53; I2 = 0%), in-hospital mortality (11 trials, 1,640 patients; OR, 0.51; 95% CI, 0.15 to 1.69), or congestive heart failure compared with controls. Similar results were seen for the risk of contrast-induced nephropathy when sodium bicarbonate was compared with normal saline alone (OR, 0.39; 95% CI, 0.20 to 0.77), but not when sodium bicarbonate/N-acetylcysteine combination was compared with N-acetylcysteine/normal saline combination (OR, 0.68; 95% CI, 0.34 to 1.37). A subgroup analysis limited to published trials showed similar results (OR, 0.26; 95% CI, 0.10 to 0.64; I2 = 63.3%), whereas unpublished studies showed a nonsignificant decrease (OR, 0.85; 95% CI, 0.46 to 1.57; I2 = 25.9%) in risk of contrast-induced nephropathy. Publication bias and heterogeneity. Hydration with sodium bicarbonate decreases the incidence of contrast-induced nephropathy in comparison to hydration with normal saline without a significant difference in need for renal replacement therapy and in-hospital mortality. Larger studies analyzing patient-centered outcomes are needed.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sodium bicarbonate concentrate, 0.1 M NaHCO3 in water, eluent concentrate for IC
Sigma-Aldrich
Sodium bicarbonate, BioXtra, 99.5-100.5%
Sigma-Aldrich
Sodium bicarbonate solution, solution (7.5%), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Sodium bicarbonate, powder, BioReagent, Molecular Biology, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Sodium bicarbonate, tested according to Ph. Eur.
USP
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Sodium bicarbonate, Vetec, reagent grade, 99%
Sigma-Aldrich
Sodium hydrogencarbonate, −40-+140 mesh, ≥95%
Sigma-Aldrich
Sodium bicarbonate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E500, 99.0-100.5%, powder
Sigma-Aldrich
Sodium bicarbonate, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Sodium bicarbonate, ACS reagent, ≥99.7%
Sigma-Aldrich
Sodium bicarbonate, ReagentPlus®, ≥99.5%, powder
Sigma-Aldrich
Sodium bicarbonate-12C, 99.9 atom % 12C